Results from a Prospective Observational Study of Men with Premature Ejaculation Treated with Dapoxetine or Alternative Care: The PAUSE Study

Dapoxetine hydrochloride is a selective serotonin reuptake inhibitor and the first drug approved for the on-demand treatment of premature ejaculation (PE). Its safety was established in a thorough clinical development program. To characterize the safety profile of dapoxetine in PE treatment and to r...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	European urology Ročník 65; číslo 4; s. 733 - 739
Hlavní autoři:	Mirone, Vincenzo, Arcaniolo, Davide, Rivas, David, Bull, Scott, Aquilina, Joseph W., Verze, Paolo
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Kidlington Elsevier B.V 01.04.2014 Elsevier
Témata:	Adolescent Adult Aged Aged, 80 and over Benzylamines - therapeutic use Biological and medical sciences Cardiovascular events Complementary Therapies Dapoxetine Gynecology. Andrology. Obstetrics Humans Male Male genital diseases Medical sciences Middle Aged Naphthalenes - therapeutic use Nephrology. Urinary tract diseases Non tumoral diseases Premature Ejaculation - therapy Prospective Studies Safety Selective Serotonin Reuptake Inhibitors - therapeutic use Syncope Urology Young Adult Cardiovascular events Safety Syncope Dapoxetine Human Nervous system diseases Nephrology Psychotropic Toxicity Consciousness impairment Sexual dysfunction Male Cardiovascular disease Care Urology Premature ejaculation Prospective Treatment Ejaculation disorders Adult Antidepressant agent Neurological disorder Male genital diseases
ISSN:	0302-2838, 1873-7560, 1873-7560
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!

Buďte první, kdo okomentuje tento záznam!